BookR: School of Health Core Facilities Booking
PubMed Publications| Keyword search (4,163 papers available) |  |
"Gauthier S" Authored Publications:
| Title | Authors | PubMed ID | |
|---|---|---|---|
| 1 | Impact of a national dementia research consortium: The Canadian Consortium on Neurodegeneration in Aging (CCNA) | Chertkow H; Phillips N; Rockwood K; Anderson N; Andrew MK; Bartha R; Beaudoin C; Bélanger N; Bellec P; Belleville S; Bergman H; Best S; Bethell J; Bherer L; Black S; Borrie M; Camicioli R; Carrier J; Cashman N; Chan S; Crowshoe L; Cuello C; Cynader M; Dang-Vu T; Das S; Dixon RA; Ducharme S; Einstein G; Evans AC; Fahnestock M; Feldman H; Ferland G; Finger E; Fisk JD; Fogarty J; Fon E; Gan-Or Z; Gauthier S; Greenwood C; Henri-Bellemare C; Herrmann N; Hogan DB; Hsiung R; Itzhak I; Jacklin K; Lanctôt K; Lim A; MacKenzie I; Masellis M; Maxwell C; McAiney C; McGilton K; McLaurin J; Mihailidis A; Mohades Z; Montero-Odasso M; Morgan D; Naglie G; Nygaard H; O' Connell M; Petersen R; Pilon R; Rajah MN; Rapoport M; Roach P; Robillard JM; Rogaeva E; Rosa-Neto P; Rylett J; Sadavoy J; St George-Hyslop P; Seitz D; Smith E; Stefanovic B; Vedel I; Walker JD; Wellington C; Whitehead V; Wittich W; | 39636028 HKAP |
| 2 | Comparison of Radiologists and Deep Learning for US Grading of Hepatic Steatosis | Vianna P; Calce SI; Boustros P; Larocque-Rigney C; Patry-Beaudoin L; Luo YH; Aslan E; Marinos J; Alamri TM; Vu KN; Murphy-Lavallée J; Billiard JS; Montagnon E; Li H; Kadoury S; Nguyen BN; Gauthier S; Therien B; Rish I; Belilovsky E; Wolf G; Chassé M; Cloutier G; Tang A; | 37787678 ENCS |
| 3 | CCCDTD5: Clinical role of neuroimaging and liquid biomarkers in patients with cognitive impairment | Brisson M; Brodeur C; Létourneau-Guillon L; Masellis M; Stoessl J; Tamm A; Zukotynski K; Ismail Z; Gauthier S; Rosa-Neto P; Soucy JP; | 33532543 PERFORM |
| 4 | Recommendations of the 5th Canadian Consensus Conference on the diagnosis and treatment of dementia. | Ismail Z, Black SE, Camicioli R, Chertkow H, Herrmann N, Laforce R, Montero-Odasso M, Rockwood K, Rosa-Neto P, Seitz D, Sivananthan S, Smith EE, Soucy JP, Vedel I, Gauthier S, CCCDTD5 participants | 32725777 PERFORM |
| 5 | Topographical distribution of Aβ predicts progression to dementia in Aβ positive mild cognitive impairment | Pascoal TA, Therriault J, Mathotaarachchi S, Kang MS, Shin M, Benedet AL, Chamoun M, Tissot C, Lussier F, Mohaddes S, Soucy JP, Massarweh G, Gauthier S, Rosa-Neto P, | 32582834 PERFORM |
| 6 | Non-invasive in vivo hyperspectral imaging of the retina for potential biomarker use in Alzheimer's disease. | Hadoux X, Hui F, Lim JKH, Masters CL, Pébay A, Chevalier S, Ha J, Loi S, Fowler CJ, Rowe C, Villemagne VL, Taylor EN, Fluke C, Soucy JP, Lesage F, Sylvestre JP, Rosa-Neto P, Mathotaarachchi S, Gauthier S, Nasreddine ZS, Arbour JD, Rhéaume MA, Beaulieu S, Dirani M, Nguyen CTO, Bui BV, Williamson R, Crowston JG, van Wijngaarden P | 31530809 PERFORM |
| 7 | The Comprehensive Assessment of Neurodegeneration and Dementia: Canadian Cohort Study. | Chertkow H, Borrie M, Whitehead V, Black SE, Feldman HH, Gauthier S, Hogan DB, Masellis M, McGilton K, Rockwood K, Tierney MC, Andrew M, Hsiung GR, Camicioli R, Smith EE, Fogarty J, Lindsay J, Best S, Evans A, Das S, Mohaddes Z, Pilon R, Poirier J, Phillips NA, MacNamara E, Dixon RA, Duchesne S, MacKenzie I, Rylett RJ | 31309917 PSYCHOLOGY |
| 8 | Brain perfusion during rapid-eye-movement sleep successfully identifies amnestic mild cognitive impairment. | Brayet P, Petit D, Baril AA, Gosselin N, Gagnon JF, Soucy JP, Gauthier S, Kergoat MJ, Carrier J, Rouleau I, Montplaisir J | 28522082 PERFORM |
| 9 | Quantification of brain cholinergic denervation in Alzheimer's disease using PET imaging with [18F]-FEOBV. | Aghourian M, Legault-Denis C, Soucy JP, Rosa-Neto P, Gauthier S, Kostikov A, Gravel P, Bédard MA | 28894304 PERFORM |
| 10 | Amyloid and tau signatures of brain metabolic decline in preclinical Alzheimer's disease. | Pascoal TA, Mathotaarachchi S, Shin M, Park AY, Mohades S, Benedet AL, Kang MS, Massarweh G, Soucy JP, Gauthier S, Rosa-Neto P, Alzheimer’s Disease Neuroimaging Initiative | 29396637 PERFORM |
| Title: | CCCDTD5: Clinical role of neuroimaging and liquid biomarkers in patients with cognitive impairment | ||||
| Authors: | Brisson M, Brodeur C, Létourneau-Guillon L, Masellis M, Stoessl J, Tamm A, Zukotynski K, Ismail Z, Gauthier S, Rosa-Neto P, Soucy JP | ||||
| Link: | https://pubmed.ncbi.nlm.nih.gov/33532543/ | ||||
| DOI: | 10.1002/trc2.12098 | ||||
| Publication: | Alzheimer' s & dementia (New York, N. Y.) | ||||
| Keywords: | |||||
| PMID: | 33532543 | Category: | Date Added: | 2021-02-03 | |
| Dept Affiliation: |
PERFORM
1 Centre hospitalier de l'université de Québec Quebec City Canada. 2 Institut universiatire de gériatrie de Montréal Montreal Canada. 3 Centre hospitalier de l'université de Montréal Montreal Canada. 4 Sunnybrook Health Sciences Centre Toronto Canada. 5 Vancouver Coastal Health, University of British-Columbia Vancouver Canada. 6 University of Alberta Edmonton Canada. 7 McMaster University Hamilton Canada. 8 Department of Psychiatry, Hotchkiss Brain Institute and O'Brien Institute for Public Health University of Calgary Calgary Canada. 9 McGill Center for Studies in Aging Canada. 10 McConnell Brain Imaging Centre, Montreal Neurological Institute Montreal Canada. 11 PERFORM Center, Concordia University Montreal Canada. |
||||
Description: |
Since 1989, four Canadian Consensus Conferences on the Diagnosis and Treatment of Dementia (CCCDTDs) have provided evidence-based dementia diagnostic and treatment guidelines for Canadian clinicians and researchers. We present the results from the Neuroimaging and Fluid Biomarkers Group of the 5th CCCDTD (CCCDTD5), which addressed topics chosen by the steering committee to reflect advances in the field and build on our previous guidelines. Recommendations on Imaging and Fluid Biomarker Use from this Conference cover a series of different fields. Prior structural imaging recommendations for both computerized tomography (CT) and magnetic resonance imaging (MRI) remain largely unchanged, but MRI is now more central to the evaluation than before, with suggested sequences described here. The use of visual rating scales for both atrophy and white matter anomalies is now included in our recommendations. Molecular imaging with [18F]-fluorodeoxyglucose ([18F]-FDG) Positron Emisson Tomography (PET) or [99mTc]-hexamethylpropyleneamine oxime/ethylene cysteinate dimer ([99mTc]-HMPAO/ECD) Single Photon Emission Tomography (SPECT), should now decidedly favor PET. The value of [18F]-FDG PET in the assessment of neurodegenerative conditions has been established with greater certainty since the previous conference, and it has now been recognized as a useful biomarker to establish the presence of neurodegeneration by a number of professional organizations around the world. Furthermore, the role of amyloid PET has been clarified and our recommendations follow those from other groups in multiple countries. SPECT with [123I]-ioflupane (DaTscanTM) is now included as a useful study in differentiating Alzheimer's disease (AD) from Lewy body disease. Finally, liquid biomarkers are in a rapid phase of development and, could lead to a revolution in the assessment AD and other neurodegenerative conditions at a reasonable cost. We hope these guidelines will be useful for clinicians, researchers, policy makers, and the lay public, to inform a current and evidence-based approach to the use of neuroimaging and liquid biomarkers in clinical dementia evaluation and management. |
